Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
1,558 questions in 115 reviews · Vascular
current versionsNo studies 346 · 22.2%Ungraded 90 · 5.8%Very low 281 · 18%Low 477 · 30.6%Moderate 313 · 20.1%High 51 · 3.3%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Extensive tests vs tests at the physician's discretion Stage of cancer ‐ early6 · people with unprovoked VTE Effect of testing for cancer on cancer‐ or venous thromboembolism (VTE)‐related mortality and morbidity in… (2021) · Cochrane | OR 5 [1.05, 23.76] | 1 study · 201 participants | Low |
Extensive tests vs tests at the physician's discretion Stage of cancer ‐ advanced8 · people with unprovoked VTE Effect of testing for cancer on cancer‐ or venous thromboembolism (VTE)‐related mortality and morbidity in… (2021) · Cochrane | OR 0.25 [0.03, 2.28] | 1 study · 201 participants | Low |
Extensive tests vs tests at the physician's discretion Time to cancer diagnosis9 · people with unprovoked VTE Effect of testing for cancer on cancer‐ or venous thromboembolism (VTE)‐related mortality and morbidity in… (2021) · Cochrane | no estimate extracted | 1 study · 201 participants | Ungraded |
Extensive tests vs tests at the physician's discretion Frequency of underlying cancer diagnosis10 · people with unprovoked VTE Effect of testing for cancer on cancer‐ or venous thromboembolism (VTE)‐related mortality and morbidity in… (2021) · Cochrane | OR 1.32 [0.59, 2.93] | 2 studies · 396 participants | Low |
Standard testing plus PET/CT scanning vs standard testing alone All‐cause mortality1 · people with unprovoked VTE Effect of testing for cancer on cancer‐ or venous thromboembolism (VTE)‐related mortality and morbidity in… (2021) · Cochrane | OR 1.22 [0.49, 3.04] | 2 studies · 1248 participants | Moderate |
Sclerotherapy vs placebo Resolution or improvement of telangiectasias ( · people with telangiectasias and reticular veins Treatment for telangiectasias and reticular veins (2021) · Cochrane | no estimate extracted | 4 studies · 613 participants | Moderate |
Sclerotherapy (polidocanol) vs sclerotherapy (any sclerosant) Adverse events ‐ matting ( · people with telangiectasias and reticular veins Treatment for telangiectasias and reticular veins (2021) · Cochrane | RR 0.82 [0.52, 1.27] | 7 studies · 859 participants | Moderate |
Sclerotherapy (polidocanol) vs sclerotherapy (any sclerosant) Pain ( · people with telangiectasias and reticular veins Treatment for telangiectasias and reticular veins (2021) · Cochrane | no estimate extracted | 5 studies · 480 participants | Moderate |
Sclerotherapy (polidocanol) vs sclerotherapy (any sclerosant) Recurrence · people with telangiectasias and reticular veins Treatment for telangiectasias and reticular veins (2021) · Cochrane | no estimate extracted | NR | No studies |
Sclerotherapy (polidocanol) vs sclerotherapy (any sclerosant) Time to resolution · people with telangiectasias and reticular veins Treatment for telangiectasias and reticular veins (2021) · Cochrane | no estimate extracted | NR | No studies |
Sclerotherapy (polidocanol) vs sclerotherapy (any sclerosant) Quality of life · people with telangiectasias and reticular veins Treatment for telangiectasias and reticular veins (2021) · Cochrane | no estimate extracted | NR | No studies |
Sclerotherapy (STS) vs sclerotherapy (any sclerosant) Resolution or improvement of telangiectasias ( · people with telangiectasias and reticular veins Treatment for telangiectasias and reticular veins (2021) · Cochrane | no estimate extracted | 4 studies · 473 participants | Moderate |
Sclerotherapy (STS) vs sclerotherapy (any sclerosant) Adverse events ‐ hyperpigmentation ( · people with telangiectasias and reticular veins Treatment for telangiectasias and reticular veins (2021) · Cochrane | RR 1.71 [1.1, 2.64] | 4 studies · 478 participants | Moderate |
Sclerotherapy (STS) vs sclerotherapy (any sclerosant) Adverse events ‐ matting ( · people with telangiectasias and reticular veins Treatment for telangiectasias and reticular veins (2021) · Cochrane | RR 2.1 [1.14, 3.85] | 2 studies · 323 participants | Moderate |
Sclerotherapy (STS) vs sclerotherapy (any sclerosant) Pain ( · people with telangiectasias and reticular veins Treatment for telangiectasias and reticular veins (2021) · Cochrane | RR 1.49 [0.99, 2.25] | 4 studies · 409 participants | Moderate |
Sclerotherapy (STS) vs sclerotherapy (any sclerosant) Recurrence · people with telangiectasias and reticular veins Treatment for telangiectasias and reticular veins (2021) · Cochrane | no estimate extracted | NR | No studies |
Sclerotherapy vs placebo Adverse events ‐ hyperpigmentation ( · people with telangiectasias and reticular veins Treatment for telangiectasias and reticular veins (2021) · Cochrane | RR 11.88 [4.54, 31.09] | 3 studies · 528 participants | Moderate |
Sclerotherapy (STS) vs sclerotherapy (any sclerosant) Time to resolution · people with telangiectasias and reticular veins Treatment for telangiectasias and reticular veins (2021) · Cochrane | no estimate extracted | NR | No studies |
Sclerotherapy (STS) vs sclerotherapy (any sclerosant) Quality of life · people with telangiectasias and reticular veins Treatment for telangiectasias and reticular veins (2021) · Cochrane | no estimate extracted | NR | No studies |
Sclerotherapy (hypertonic saline) vs sclerotherapy (any sclerosant) Resolution or improvement of telangiectasias ( · people with telangiectasias and reticular veins Treatment for telangiectasias and reticular veins (2021) · Cochrane | no estimate extracted | 3 studies · 348 participants | Moderate |
Sclerotherapy (hypertonic saline) vs sclerotherapy (any sclerosant) Adverse events ‐ hyperpigmentation ( · people with telangiectasias and reticular veins Treatment for telangiectasias and reticular veins (2021) · Cochrane | RR 0.74 [0.59, 0.93] | 2 studies · 288 participants | Moderate |
Sclerotherapy (hypertonic saline) vs sclerotherapy (any sclerosant) Adverse events ‐ matting ( · people with telangiectasias and reticular veins Treatment for telangiectasias and reticular veins (2021) · Cochrane | RR 0.89 [0.58, 1.36] | 2 studies · 288 participants | Moderate |
Sclerotherapy (hypertonic saline) vs sclerotherapy (any sclerosant) Pain ( · people with telangiectasias and reticular veins Treatment for telangiectasias and reticular veins (2021) · Cochrane | no estimate extracted | 3 studies · 348 participants | Moderate |
Sclerotherapy (hypertonic saline) vs sclerotherapy (any sclerosant) Recurrence · people with telangiectasias and reticular veins Treatment for telangiectasias and reticular veins (2021) · Cochrane | no estimate extracted | NR | No studies |
Sclerotherapy (hypertonic saline) vs sclerotherapy (any sclerosant) Time to resolution · people with telangiectasias and reticular veins Treatment for telangiectasias and reticular veins (2021) · Cochrane | no estimate extracted | NR | No studies |
Sclerotherapy (hypertonic saline) vs sclerotherapy (any sclerosant) Quality of life · people with telangiectasias and reticular veins Treatment for telangiectasias and reticular veins (2021) · Cochrane | no estimate extracted | NR | No studies |
Sclerotherapy (chromated glycerin) vs sclerotherapy (any sclerosant) Resolution or improvement of telangiectasias ( · people with telangiectasias and reticular veins Treatment for telangiectasias and reticular veins (2021) · Cochrane | no estimate extracted | 2 studies · 125 participants | Low |
Sclerotherapy vs placebo Adverse events ‐ matting ( · people with telangiectasias and reticular veins Treatment for telangiectasias and reticular veins (2021) · Cochrane | RR 4.06 [1.28, 12.84] | 3 studies · 528 participants | Moderate |
Sclerotherapy (chromated glycerin) vs sclerotherapy (any sclerosant) Adverse events ‐ hyperpigmentation ( · people with telangiectasias and reticular veins Treatment for telangiectasias and reticular veins (2021) · Cochrane | RR 0.49 [0.09, 2.5] | 2 studies · 125 participants | Low |
Sclerotherapy (chromated glycerin) vs sclerotherapy (any sclerosant) Adverse events ‐ matting ( · people with telangiectasias and reticular veins Treatment for telangiectasias and reticular veins (2021) · Cochrane | RR 0.31 [0.01, 7.53] | 1 study · 99 participants | Low |
Sclerotherapy (chromated glycerin) vs sclerotherapy (any sclerosant) Pain ( · people with telangiectasias and reticular veins Treatment for telangiectasias and reticular veins (2021) · Cochrane | RR 1.5 [0.3, 7.55] | 1 study · 26 participants | Low |
Sclerotherapy (chromated glycerin) vs sclerotherapy (any sclerosant) Recurrence · people with telangiectasias and reticular veins Treatment for telangiectasias and reticular veins (2021) · Cochrane | no estimate extracted | NR | No studies |
Sclerotherapy (chromated glycerin) vs sclerotherapy (any sclerosant) Time to resolution · people with telangiectasias and reticular veins Treatment for telangiectasias and reticular veins (2021) · Cochrane | no estimate extracted | NR | No studies |
Sclerotherapy (chromated glycerin) vs sclerotherapy (any sclerosant) Quality of life · people with telangiectasias and reticular veins Treatment for telangiectasias and reticular veins (2021) · Cochrane | no estimate extracted | NR | No studies |
Foam vs sclerotherapy (any sclerosant) Resolution or improvement of telangiectasias ( · people with telangiectasias and reticular veins Treatment for telangiectasias and reticular veins (2021) · Cochrane | no estimate extracted | 2 studies · 187 participants | Low |
Foam vs sclerotherapy (any sclerosant) Adverse events ‐ hyperpigmentation ( · people with telangiectasias and reticular veins Treatment for telangiectasias and reticular veins (2021) · Cochrane | RR 2.12 [0.44, 10.23] | 2 studies · 187 participants | Low |
Foam vs sclerotherapy (any sclerosant) Adverse events ‐ matting ( · people with telangiectasias and reticular veins Treatment for telangiectasias and reticular veins (2021) · Cochrane | RR 6.12 [1.04, 35.98] | 2 studies · 187 participants | Low |
Foam vs sclerotherapy (any sclerosant) Pain ( · people with telangiectasias and reticular veins Treatment for telangiectasias and reticular veins (2021) · Cochrane | no estimate extracted | 1 study · 147 participants | Low |
Sclerotherapy vs placebo Pain ( · people with telangiectasias and reticular veins Treatment for telangiectasias and reticular veins (2021) · Cochrane | no estimate extracted | 1 study · 40 participants | Low |
Foam vs sclerotherapy (any sclerosant) Recurrence · people with telangiectasias and reticular veins Treatment for telangiectasias and reticular veins (2021) · Cochrane | no estimate extracted | NR | No studies |
Foam vs sclerotherapy (any sclerosant) Time to resolution · people with telangiectasias and reticular veins Treatment for telangiectasias and reticular veins (2021) · Cochrane | no estimate extracted | NR | No studies |
Foam vs sclerotherapy (any sclerosant) Quality of life · people with telangiectasias and reticular veins Treatment for telangiectasias and reticular veins (2021) · Cochrane | no estimate extracted | NR | No studies |
Laser vs sclerotherapy Resolution or improvement of telangiectasias ( · people with telangiectasias and reticular veins Treatment for telangiectasias and reticular veins (2021) · Cochrane | no estimate extracted | 5 studies · 593 participants | Moderate |
Laser vs sclerotherapy Adverse events ‐ hyperpigmentation ( · people with telangiectasias and reticular veins Treatment for telangiectasias and reticular veins (2021) · Cochrane | RR 0.57 [0.4, 0.8] | 4 studies · 262 participants | Moderate |
Laser vs sclerotherapy Adverse events ‐ matting ( · people with telangiectasias and reticular veins Treatment for telangiectasias and reticular veins (2021) · Cochrane | RR 1 [0.46, 2.19] | 2 studies · 162 participants | Moderate |
Laser vs sclerotherapy Pain ( · people with telangiectasias and reticular veins Treatment for telangiectasias and reticular veins (2021) · Cochrane | no estimate extracted | 2 studies · 100 participants | Low |
Laser vs sclerotherapy Recurrence · people with telangiectasias and reticular veins Treatment for telangiectasias and reticular veins (2021) · Cochrane | no estimate extracted | NR | No studies |
Laser vs sclerotherapy Time to resolution · people with telangiectasias and reticular veins Treatment for telangiectasias and reticular veins (2021) · Cochrane | no estimate extracted | NR | No studies |
Laser vs sclerotherapy Quality of life · people with telangiectasias and reticular veins Treatment for telangiectasias and reticular veins (2021) · Cochrane | no estimate extracted | NR | No studies |
Sclerotherapy vs placebo Recurrence · people with telangiectasias and reticular veins Treatment for telangiectasias and reticular veins (2021) · Cochrane | no estimate extracted | NR | No studies |